|
|
本帖最后由 xxtrader 于 2009-5-27 14:44 编辑
最近INSIDER BUY 这个INDICATOR好像特别准总是提前1-2天
今天LOAD KERX晚了，不过还是大赚了不少，看了这个的同志们有关注吗？http://www.hutong9.com/viewthread.php?tid=50075&extra=page%3D1 别告诉我你没关注。
KERX ROX
ROX看样子还来得及 ， 另外俺刚抛了KERX,不是KERX不好（很强的上升趋势，但能否持久还不确定，先跑路锁定利润再说），而且还因为ACUS , NEPH 价格实在太诱惑俺了，俺逢低+KERX赚的利润又LOAD 了不少ACUS,和NEPH,看好这两只最近有动作（ACUS不该是FDA，还早,但好像有别的什么，也许和它JV 公司有关，俺现在还不确定，但老是觉得它蠢蠢欲动，不敢买的就先关注吧）
另外还有我以前不知道在哪里订购的一个选股网站最近连续两天给我发的推荐都非常的准，这个是俺忽视了，俺很少看网站推荐的股票，因为一般SPAM很多，俺直接都删除的，但这次好像我错了，我会再第一时间把它最近推荐的陆续贴上来给大家参考（只是参考），这个是它前天和昨天给俺发的，大家明鉴（当然里面也会少不了SPAM)
Tuesday's Watch List - Breaking News Issued for IECM, CYTK, MAPP 这个和这个昨天就狂飙
Tuesday May 26, 2009
InteleCom, Inc. (OTC: IECM) --- BREAKING NEWS
InteleCom International Distribution Expands to the Philippines, Mexico, and Thailand on Revolutionary $39.95 CoIP Technology
InteleCom expects significant sales in the next 60 days as they get their team of master distributors seated and selling through their organizations. InteleCom believes it is on track to meet its initial forecast of $30Mil in revenues in 2009. Read Full Story
******************************************************* Cytokinetics Incorporated (CYTK) --- BREAKING NEWS
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Under the terms of the companies' 2006 collaboration and option agreement, Amgen has agreed to pay Cytokinetics a non-refundable exercise fee of $50 million and has assumed responsibility for development and commercialization of CK-1827452 and related compounds, at its expense, subject to specified development and commercial participation rights of Cytokinetics.. Read Full Story
*******************************************************
MAP Pharmaceuticals, Inc. (MAPP) --- BREAKING NEWS
MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Read Full Story
这个是它推荐今天要关注的
05/27/2009
Ceregene, Inc. (NASDAQ: CEGE) --- BREAKING NEWS
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson's disease patients in order to restore the function and protect degenerating nigrostriatal neurons.
Read Full Story
*******************************************************
Power Medical Interventions(r), Inc. (OTCBB: PMII) --- BREAKING NEWS
PMI Prepared to Launch Next Generation Intelligent Surgical Instrument(tm) Platform
Power Medical Interventions(r), Inc. (OTCBB:PMII), a leader in developing and commercializing Intelligent Surgical Instruments(tm), announced today that the U.S. Food and Drug Administration (FDA) has cleared its 510(k) application for marketing its iDrive Intelligent Power Unit(tm), detachable Intelligent Surgical Instruments and iConsole(tm). Based on the marketing clearance by the FDA, Power Medical Interventions (PMI) intends to launch the iDrive, Intelligent Surgical Instruments and iConsole products for commercial sale, effective immediately.
Read Full Story
*******************************************************
CombinatoRx, Incorporated (NASDAQ: CRXX) --- BREAKING NEWS
CombinatoRx Reports Positive Phase 2 Trial Results for CRx-401
CombinatoRx, today reported positive results for its Phase 2 clinical study of CRx-401 as an add-on to metformin therapy in Type 2 diabetes. Results from this trial demonstrated that CRx-401 (a synergistic combination of bezafibrate and diflunisal) performed statistically significantly better than bezafibrate on the primary efficacy endpoint of reduction in fasting plasma glucose (FPG) at day 90 with a difference of 12 mg/dL (p=0.049).
*******************************************************
Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R)
PETALUMA, Calif., -- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS),这个今天好像涨了不少 a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Microcyn(R) Skin and Wound Gel as both a prescription and over-the-counter formulation. The Rx product, under the supervision of a health care professional, is intended for management of exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically debrided wounds. This is the first hydrogel product based upon the Microcyn Technology platform and is reimbursable by both Medicare and Medicaid.
这个是今天早上才收到，所以这个网站发垃圾给我的时间不定，最近两天倒真是发钱给我来的，我又忽略了，但今天的关注发的太晚，不像昨天，25号就发来了，所以有时候会来不及
明天的关注，不知道它是今天发来还是明天，反正俺会第一时间转这里，有兴趣的朋友就来看看吧（声明，因为这类的网站推荐里面一定会有SPAM,大家要小心啊）
受到MAPP的启发，俺今晚会挑一些类似MAPP这样的，不想大家错过了，晚上选好再发出来，现在不多说了，再去捞点便宜货，晚上见
PS.有兴趣的朋友可以关注下AGEN, 俺总觉得它有点MAPP和OCLS的感觉 错了，其实俺更觉得它有DNDN的感觉 |
|
狗仔卡
发表于 2009-5-27 01:29 PM
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
